Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a gentle brain zap help breast cancer survivors think clearly again?

NCT ID NCT02726763

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS), combined with cognitive training, is feasible and tolerable for breast cancer survivors who have memory or thinking problems after chemotherapy. The study will enroll 18 survivors aged 40-65 who completed treatment at least six months ago. The goal is to see if this approach is practical and well-tolerated, not yet to measure effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device
What this could lead to
If it works, this could point toward a non-drug way to help memory problems in breast cancer survivors after chemotherapy.
What could go wrong
This is a very small pilot study with only 18 people, so it can't prove effectiveness. It only checks if the approach is practical and tolerable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Mar 2016

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Breast cancer survivors treated with chemotherapy between 40 and 65 years of age with no evidence of disease with treatment completed at least six months prior to study participation with or without current endocrine therapy. * Self-reported new onset since initiation of treatment cognitive dysfunction as determined by telephone screen using the brief (3 questions) assessment established by Ercoli et al. \[3\] (endorsement on all three questions): 1. Do you think or feel that your memory or mental ability has gotten worse since you completed your breast cancer treatment? 2. Do you think that your mind isn't as sharp now as it was before your breast cancer treatments? 3. Do you feel like these problems have made it harder to function on your job or take care of things around the home? * In the judgment of the investigators and/or consenting professional, able to read and comprehend English * In the judgment of the consenting professional cognitively able to provide informed consent Exclusion Criteria: * Patients with prior history of primary Central Nervous System (CNS) cancer or CNS metastases * As per self report and/or medical record history of diagnosed neurological illness including seizure disorder, a dementing condition, or other neurological illness (multiple sclerosis, history of cerebrovascular accident, etc.) * Participants with untreated depression or anxiety as assessed by self-report and review of medical history; * Participants with a history of treated or untreated schizophrenia or bipolar disorder as assessed by self report and review of medical history; * As per self report participants who are pregnant or who are breastfeeding * As per self report participants with pacemakers, intracranial electrodes, implanted defibrillators or any other prosthesis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.